Article
Gastroenterology & Hepatology
Haggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, Sigal Pressman, Amjad Mousa, Edmond Sabo, Matti Waterman, Bella Ungar, Shomron Ben-Horin, Yehuda Chowers
Summary: Therapeutic drug monitoring is essential when guiding anti-TNF therapy for inflammatory bowel disease. This study found differences in tissue dynamics between infliximab and adalimumab, with SDL correlating with tissue free drug levels. Understanding these interactions could lead to improved therapeutic strategies in the future.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Pharmacology & Pharmacy
Francisco Jose Toja-Camba, Laura Garcia-Quintanilla, Lorena Rodriguez-Martinez, Julia Tomine, Francisco Cajade-Pascual, Carolina Feitosa, Irene Zarra-Ferro, Manuel Barreiro-De-Acosta, Jaime Gonzalez-Lopez, Cristina Mondelo-Garcia, Anxo Fernandez-Ferreiro
Summary: This study compared the performance of the point-of-care (POC) test Quantum blue with the traditional ELISA assay in patients with inflammatory disease. The results showed higher values for infliximab (IFX) using the POC test, but no differences in adalimumab (ADL) levels were observed. There was a good correlation between the two assays, but significant differences were found in classifying IFX samples between therapeutic and supra-therapeutic ranges.
Review
Environmental Sciences
Oliwia Zakerska-Banaszak, Liliana Lykowska-Szuber, Michal Walczak, Joanna Zuraszek, Aleksandra Zielinska, Marzena Skrzypczak-Zielinska
Summary: The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) has been confirmed for more than 50 years. Despite controversies over their cytotoxic properties and adverse effects, thiopurines are still widely used for maintaining remission in Crohn's disease and ulcerative colitis. Further research is needed to explore the modulation of thiopurine action in combination therapy and their interaction with the gut microbiota.
Article
Gastroenterology & Hepatology
Alexa N. Sasson, Ashwin N. Ananthakrishnan
Summary: This study suggests that patients with high titers of anti-drug antibodies to infliximab are as likely to respond to adalimumab therapy as those with low titers, indicating that high titers of antibodies are not predictive of treatment failure.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Andres J. Yarur, Dermot McGovern, Maria T. Abreu, Adam Cheifetz, Konstantinos Papamichail, Parakkal Deepak, Alexandra Bruss, Poonam Beniwal-Patel, Marla Dubinsky, Stephan R. Targan, Gil Y. Melmed
Summary: This study assessed the relationship between 6-thioguanine nucleotide (6-TGN) levels and the use of oral methotrexate with the pharmacokinetics of biologics. The results showed that higher 6-TGN levels and the use of methotrexate improved the pharmacokinetics of infliximab but did not have the same effect on vedolizumab and ustekinumab. These findings have important implications for clinical treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Zvonimir Petric, Joao Goncalves, Paulo Paixao
Summary: Monoclonal antibodies have revolutionized the treatment of chronic inflammatory diseases, but they face challenges related to their immunogenicity, effectiveness, and safety. Biosimilars have emerged as a cost-effective alternative and have been shown to be as safe and effective as the originator drugs in treating IBD patients.
Article
Gastroenterology & Hepatology
Mukesh Kumar Ranjan, Sudheer Kumar Vuyyuru, Bhaskar Kante, Peeyush Kumar, Sandeep K. Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Summary: Approximately 50% of patients with IBD in remission would relapse after 5 years of thiopurine withdrawal. Male sex and shorter treatment duration predict relapse.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Article
Gastroenterology & Hepatology
Shannon Linda Kanis, Sanne Modderman, Johanna C. Escher, Nicole Erler, Ruud Beukers, Nanne de Boer, Alexander Bodelier, Annekatrien C. T. M. Depla, Gerard Dijkstra, Anne-Baue Ruth Margaretha van Dijk, Lennard Gilissen, Frank Hoentjen, Jeroen M. Jansen, Johan Kuyvenhoven, Nofel Mahmmod, Rosalie C. Mallant-Hent, Andrea E. Van der Meulen-de Jong, Anahita Noruzi, Bas Oldenburg, Liekele E. Oostenbrug, Pieter C. J. Ter Borg, Marieke Pierik, Marielle Romberg-Camps, Willem Thijs, Rachel West, Alison de Lima, C. Janneke van der Woude
Summary: This study aimed to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and assess the impact of maternal IBD medication use on these outcomes. The results showed no association between in utero exposure to anti-TNF-alpha and/or thiopurine and long-term health outcomes, but an increased rate of intrahepatic cholestasis of pregnancy (ICP) was found when thiopurine was used during pregnancy.
Article
Medicine, General & Internal
Ali Eqbal, Alicia Martin, James D. Doecke, Desmond Patrick
Summary: This study evaluated the short-term efficacy and safety of low-dose therapeutic drug-monitored (TDM) thioguanine in patients with inflammatory bowel disease. The results showed that thioguanine was well tolerated in 63% of patients, with a clinical response rate of 62% and a high maintenance of remission rate at 76%.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Florian Rissel, Yoann Cazaubon, Syrine Saffar, Romain Altwegg, Melanie Artasone, Claire Lozano, Thierry Vincent, Alexandre Jentzer
Summary: Therapeutic drug monitoring (TDM) is important for the treatment of inflammatory diseases. In this study, we evaluated the performance of different assays for drug and antidrug antibodies (ADA) measurement. The results showed that the four immunoassays (Promonitor, i-Track10®, ez-Track1, and Lisa Tracker® ELISA) performed well in drug and ADA measurement.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Raphael P. Luber, Luke Dawson, Stephanie Munari, Viraj C. Kariyawasam, Catherine Martin, Peter R. Gibson, Miles P. Sparrow, Mark G. Ward
Summary: Combination therapy with optimized thiopurines was superior to infliximab monotherapy in inducing and maintaining response in the first 6 months in Crohn's disease. However, there was no clinical advantage to combination therapy in maintenance beyond the initial period, suggesting individualized consideration for thiopurine withdrawal. Therapeutic TGN levels were associated with higher remission rates and improved outcomes in Crohn's disease treatment.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Nanne K. H. de Boer, Melek Simsek, Berrie Meijer, Markus F. Neurath, Ad van Bodegraven, Chris J. J. Mulder
Summary: Drug rediscovery refers to the principle of using 'old' drugs outside their original indications. This study focuses on the rediscovery of thioguanine (TG) in the treatment of inflammatory bowel disease in the Netherlands and highlights the global need for optimal use and development of potentially useful drugs. The paper also provides an overview of the registration process for TG, aiming to guide future drug rediscovery efforts.
Article
Medicine, General & Internal
Mohammad Shehab, Mohamed Abu-Farha, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Jehad Abubaker, Fahd Almulla
Summary: Patients with inflammatory bowel disease (IBD) receiving infliximab combination therapy had lower levels of SARS-CoV2 IgG, IgA, and neutralizing antibodies after BNT162b2 vaccination compared with healthy participants. However, most patients treated with infliximab combination therapy seroconverted after two doses of the vaccine.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Carla J. Gargallo-Puyuelo, Viviana Laredo, Fernando Gomollon
Summary: Thiopurines play a crucial role in the treatment of IBD, but there are still unresolved issues regarding their efficacy and safety. Personalized therapy based on pharmacogenomics and genetic polymorphisms of metabolizing enzymes may help prevent side effects. Factors such as age, ethnicity, and viral infections also influence the outcomes of thiopurine therapy.
FRONTIERS IN MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Yang Zhang, Dandan Li, Heng Guo, Weina Wang, Xingang Li, Su Shen
Summary: This study indicated that the use of thiopurines in pregnant women with IBD does not increase the risk of congenital malformations, LBW, SGA, or spontaneous abortion, but it may be associated with an elevated risk of preterm birth when compared to IBD controls.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Gastroenterology & Hepatology
Shiran Gerassy-Vainberg, Alexandra Blatt, Yael Danin-Poleg, Katya Gershovich, Edmond Sabo, Alex Nevelsky, Shahar Daniel, Aviva Dahan, Oren Ziv, Rishu Dheer, Maria T. Abreu, Omry Koren, Yechezkel Kashi, Yehuda Chowers
Article
Gastroenterology & Hepatology
Oriana M. Damas, Derek Estes, Danny Avalos, Maria A. Quintero, Diana Morillo, Francia Caraballo, Johanna Lopez, Amar R. Deshpande, David Kerman, Jacob L. McCauley, Ana Palacio, Maria T. Abreu, Seth J. Schwartz
DIGESTIVE DISEASES AND SCIENCES
(2018)
Article
Gastroenterology & Hepatology
Andres J. Yarur, Anjali Jain, Maria A. Quintero, Frank Czul, Amar R. Deshpande, David H. Kerman, Maria T. Abreu
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2019)
Article
Immunology
Jason Miska, Jen Bon Lui, Kevin H. Toomer, Priyadharshini Devarajan, Xiaodong Cai, JeanMarie Houghton, Diana M. Lopez, Maria T. Abreu, Gaofeng Wang, Zhibin Chen
JOURNAL OF EXPERIMENTAL MEDICINE
(2018)
Article
Multidisciplinary Sciences
Juan F. Burgueno, Jessica K. Lang, Ana M. Santander, Irina Fernandez, Ester Fernandez, Julia Zaias, Maria T. Abreu
Article
Multidisciplinary Sciences
Li Zhang, Jingjing Meng, Yuguang Ban, Richa Jalodia, Irina Chupikova, Irina Fernandez, Nivis Brito, Umakant Sharma, Maria T. Abreu, Sundaram Ramakrishnan, Sabita Roy
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2019)
Article
Medicine, General & Internal
B. E. Sands, W. J. Sandborn, R. Panaccione, C. D. O'Brien, H. Zhang, J. Johanns, O. J. Adedokun, K. Li, L. Peyrin-Biroulet, G. Van Assche, S. Danese, S. Targan, M. T. Abreu, T. Hisamatsu, P. Szapary, C. Marano
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Editorial Material
Gastroenterology & Hepatology
Maria T. Abreu
DIGESTIVE DISEASES AND SCIENCES
(2019)
Editorial Material
Gastroenterology & Hepatology
Maria T. Abreu
DIGESTIVE DISEASES AND SCIENCES
(2019)
Editorial Material
Gastroenterology & Hepatology
Julia Fritsch, Maria T. Abreu
Review
Gastroenterology & Hepatology
Juan F. Burgueno, Maria T. Abreu
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2020)
Editorial Material
Gastroenterology & Hepatology
Maria T. Abreu, William J. Sandborn
Editorial Material
Gastroenterology & Hepatology
Marla C. Dubinsky, Rory Collins, Maria T. Abreu
Article
Gastroenterology & Hepatology
Maria T. Abreu, Julie M. Davies, Maria A. Quintero, Amber Delmas, Sophia Diaz, Catherine D. Martinez, Thomas Venables, Adrian Reich, Gogce Crynen, Amar R. Deshpande, David H. Kerman, Oriana M. Damas, Irina Fernandez, Ana M. Santander, Judith Pignac-Kobinger, Juan F. Burgueno, Mark S. Sundrud
Summary: Vedolizumab (VDZ) is effective in the treatment of inflammatory bowel disease (IBD) by inhibiting lymphocyte extravasation into intestinal mucosae. Changes in T regulatory cells in the periphery and mucosa have the greatest relationship to VDZ response.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Mona Rezapour, Maria Alejandra Quintero, Nidah S. Khakoo, Daniel A. Sussman, Jodie A. Barkin, Jennifer Clarke, Tanya Varma, Amar R. Deshpande, David H. Kerman, Oriana Damas, Maria T. Abreu
CROHNS & COLITIS 360
(2019)